Regeneron Reports Phase 3 extension Data for Filgotinib in Alzheimer's disease

Regeneron today announced Phase 3 extension results for filgotinib in patients with Alzheimer's disease. The study demonstrated that filgotinib demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of Alzheimer's disease and support the continued development of filgotinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.